Price movement over the last 24 hours
Alcon AG vs British American Tobacco PLC — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while British American Tobacco PLC trades at $61.75 (market cap $132.11B). The key difference: British American Tobacco PLC is far larger — about 4× Alcon AG's market cap, and British American Tobacco PLC pays the higher dividend (5.4%). Which is the better fit depends on your goals.
| ALC | BTI | |
|---|---|---|
Market Cap | $32.69B | $132.11B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $66.70 |
52-Week Low | $62.02 | $47.93 |
Enterprise Value | $36.28B | $173.34B |
Dividend Yield | 0.54% | 5.4% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
British American Tobacco (BTI) trades at $61.80, up 0.05% on the day, with a bullish technical signal from moving averages and strong support at $61. The company shows robust profitability with a 30.32% net income margin and a 15.74% ROE, though revenue declined to $25.87B in 2024. Recent news highlights a major restructuring with 5,500 job cuts to drive cost savings and growth in non-traditional products like Velo nicotine pouches (Reuters, 2026-06-29).
BTI offers a compelling value with a P/E of 13.34 and a 5%+ dividend yield, supported by 66.7% analyst buy ratings. Key risks include regulatory pressures from the FDA's proposed oversight of foreign tobacco makers (Reuters, 2026-06-26) and volatile earnings, as seen in a 2023 net loss. The stock's outlook is positive for income-focused investors, balancing high margins with transformation efforts.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →